• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Company Analysis - Alembic Limited Product Image

Company Analysis - Alembic Limited

  • Published: November 2007
  • Region: Global
  • 30 Pages
  • RNCOS E-Services Private Limited

Company Analysis assists individual investors, managers and companies in evaluating opportunities, trends, market innovations as well as in selecting appropriate information solutions in order to make effective investment decisions.

The study covers information on the business structure, areas of operation, products and services offered by the company. It comprises SWOT analysis, Key Ratios, and financials that aid investors in gaining an insight into the company’s performance.

The report is based on extensive research using data available from credible publications, trade journals, industry associations and the company sources.

Report Highlights

- Provides a comprehensive version of the company’s performance
- Offers key financial data, ratio and SWOT analysis
- Tracks major M&A trends and developments
- Business Profile, SWOT analysis and financial information on top five competitors
- View on the company by our analysts
- Supplemented with graphs and tabular information wherever necessary

1. Company Overview
1.1 History
1.2 Business Overview
1.3 Organizational Structure
1.4 Ticker Codes at various Stock Exchange Listings
1.5 Major Mergers & Acquisitions
1.6 Management Profile

2. Product & Services
2.1 Product & Services - An Overview
2.2 Revenue & Income Summary by Business Segment
2.3 Revenue & Income Summary by Geographical Distribution

3. Financial Information for the Fiscal Year
3.1 Financial Summary for the Fiscal Year
3.2 Breakup of Revenue & Sales Trends
3.3 Ratio & Market Indicators
3.4 Earning & Income Estimates

4. SWOT Analysis
4.1 Strength
4.2 Weaknesses
4.3 Opportunity
4.4 Threats

5. Top Competitors
5.1 Ranbaxy Laboratories Limited
5.2 Lupin Limited
5.3 Cipla Limited
5.4 Zydus Cadila Healthcare Limited
5.5 Glaxo Smithkline Pharmaceuticals Limited

6. Analyst View

List of Tables

Table 1 1: Alembic Limited - Ticker Codes at various Stock Exchanges
Table 1 2: Alembic Limited - Major Mergers & Acquisitions (2003 to 2007)
Table 1 3: Alembic Limited - Key Management People
Table 3 1: Alembic Limited - Financials Overview (in Million Rs), March 2007
Table 3 2: Alembic Limited - Breakup of Revenue & Sales (in Million Rs), March 2005 to March 2007
Table 3 3: Alembic Limited - Key Financial Ratios (March 2005 to March 2007)
Table 3 4: Alembic Limited - Earning & Income Estimates (in Thousand Rs), March 2005 to March 2007
Table 5 1: Ranbaxy Laboratories Limited - Key Financials (in Million Rs), 2004-2006
Table 5 2: Ranbaxy Laboratories Limited - SWOT Analysis
Table 5 3: Lupin Limited - Key Financials (in Million Rs), March 2005 to March 2007
Table 5 4: Lupin Limited - SWOT Analysis
Table 5 5: Cipla Limited - Key Financials (in Rs Crore), 2005-06 & 2006-07
Table 5 6: Cipla Limited - SWOT Analysis
Table 5 7: Zydus Cadila Healthcare Limited - Key Financials (in Million Rs), March 2004 to March 2006
Table 5 8: Zydus Cadila Healthcare Limited - SWOT Analysis
Table 5 9: Glaxo Smithkline Pharmaceuticals Limited - Key Financials (in Rs Lakh), 2005 & 2006
Table 5 10: Glaxo Smithkline Pharmaceuticals Limited - SWOT Analysis

List of Figures

Figure 2 1: Alembic Limited - Gross Revenue by Business Segment (in Million Rs), March 2006 & March 2007
Figure 2 2: Alembic Limited - Gross Revenue by Geographical Distribution (in Million Rs), March 2006 & March 2007

Note: Product cover images may vary from those shown

RELATED PRODUCTS